Riely, Gregory J <br/><br/>
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Sep 2007 
 - 5150-5 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-07-0560  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carcinoma, Non-Small-Cell Lung--diagnostic imaging<br/>Drug Resistance, Neoplasm<br/>Erlotinib Hydrochloride<br/>Everolimus<br/>Female<br/>Fluorodeoxyglucose F18<br/>Gefitinib<br/>Humans<br/>Lung Neoplasms--diagnostic imaging<br/>Male<br/>Middle Aged<br/>Positron-Emission Tomography<br/>Prospective Studies<br/>Protein Kinase Inhibitors--therapeutic use<br/>Quinazolines--therapeutic use<br/>Sirolimus--administration & dosage<br/>Tomography, X-Ray Computed